Post by Topas Therapeutics GmbH

🔙 Glad to be back at the Antigen-Specific Immune Tolerance Summit!    Topas’ leadership team Hugo Fry and Cristina de Min will be attending with clinical data, fresh insights and ideas on how to improve drug development in autoimmune disease as the global ASIT community reunites in Boston early March.    🫵 Join Cristina’s presentation to learn how Topas integrates biological insights with innovative clinical trial design to assess antigen-specific immune tolerance induction. The talk will also highlight our approach to selecting meaningful endpoints and advanced analytical methods, including non-invasive biomarkers, to reliably evaluate and advance precision immunotherapies like #TPM502 in celiac disease.    📍 Hilton Boston Logan Airport Hotel  ⏲️ DAY ONE - Wednesday, March 4, 9:30 am ET  ▶️ https://lnkd.in/dA-EMEiC    #ASITSummit #Autoimmunity #CeliacDisease #T1D #Type1Diabetes #ImmuneTolerance #ToleranceInduction #TopasTherapeutics